Wells Fargo analyst Larry Biegelsen started coverage of ShockWave Medical with a Market Perform rating and a $33 price target. The analyst believes the company’s intravascular lithotripsy is an innovative technology that has several key advantages over the competition, and that it will be able to both grow the market opportunity for calcium modification devices and take share from the atherectomy players. That stated, at current valuations, Biegelsen does not see the potential for meaningful multiple expansion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.